Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

chop

chop is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 2
Pipeline programs 15
News articles 0
Drug details — chop
Class
—
Route
—
Patents
2
Programs
15
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

chop is an FDA-listed pharmaceutical active ingredient.

Key facts

INN chop

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Azithromycin Phase 3 · Cardiff Oncology · Bronchopulmonary Dysplasia
  2. BuS2020 Phase 3 · George Institute for · Bronchopulmonary dysplasia, Preterm newborns ≤32 weeks of ge
  3. dexamethasone Phase 3 · Ultragenyx UK · Bronchopulmonary Dysplasia
  4. lipegfilgrastim Phase 3 · Teva Pharma · Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-C
  5. CHOP+selinexor+5-Azacitidine Phase 2 · Chinese Academy of · Peripheral T Cell Lymphoma
  6. FIL_RI-CHOP Phase 2 · Telethon Foundation · Diffuse Large B-cell Lymphoma ABC
  7. IRST100.60 Phase 2 · Istituto Gentili Italia · NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs
  8. Lenalidomide combined with G-CHOP (LO CHOP) Phase 2 · First People's Hospital · DLBCL - Diffuse Large B Cell Lymphoma

Related patents

Browse patents

  1. US 10738123

    Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. EP 2446891

    Semuloparin für Verwendung als eine antithrombotische Behandlung in den großen Bauchoperation mit verbesserter Sicherheit in Bezug auf klinisch relevante Blutungen und starken Blutungen

    Expires Tue Apr 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is chop?

chop is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.